Scilex Holding Company (SCLX)
(Delayed Data from NSDQ)
$1.15 USD
+0.04 (3.60%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SCLX 1.15 +0.04(3.60%)
Will SCLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SCLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SCLX
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
SCLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Other News for SCLX
Scilex to present on ZTlido at 2024 Annual PAINWeek Conference
Scilex announces FDA final approval to precision dosing for GLOPERBA label
SCLX Stock Earnings: Scilex Holding Misses EPS, Beats Revenue for Q2 2024
Scilex signs distribution agreement for ZTlido for parts of Africa, Middle East
Scilex reports preliminary July product sales $4.3M-$5.3M vs $2.8M last year